Ming-yi Yang

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Anti-TIGIT in PD-L1-High Advanced Non-Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward.

Anti-TIGIT in PD-L1-High Advanced Non-Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Metformin-Based Covalent Organic Frameworks With Excellent Biosafety and High Efficiency against Pathogenic Microorganisms.

Metformin-Based Covalent Organic Frameworks With Excellent Biosafety and High Efficiency against Pathogenic Microorganisms.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: November 06, 2025

The Coordination Microenvironment Tailoring in 2D MOFs for Enhancing Photocatalytic Acetylene Semi-Hydrogenation.

The Coordination Microenvironment Tailoring in 2D MOFs for Enhancing Photocatalytic Acetylene Semi-Hydrogenation.

Journal: Angewandte Chemie (International ed. in English)

Published: October 09, 2025

Efficient Solar-Driven Electrocatalytic Halogen-Mediated Ethylene Oxidation in Seawater by Metallophthalocyanine-Based COFs.

Efficient Solar-Driven Electrocatalytic Halogen-Mediated Ethylene Oxidation in Seawater by Metallophthalocyanine-Based COFs.

Journal: Angewandte Chemie (International ed. in English)

Published: September 18, 2025

One-Dimensional Covalent Organic Frameworks: From Design, Synthesis to Applications.

One-Dimensional Covalent Organic Frameworks: From Design, Synthesis to Applications.

Journal: Angewandte Chemie (International ed. in English)

Published: March 27, 2025

Hydrogen-Localization Transfer Regulation in 3D COFs Enhances Photocatalytic Acetylene Semi-Hydrogenation to Ethylene.

Hydrogen-Localization Transfer Regulation in 3D COFs Enhances Photocatalytic Acetylene Semi-Hydrogenation to Ethylene.

Journal: Angewandte Chemie (International ed. in English)

Published: November 26, 2024

Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: November 20, 2024

A Novel DNA Repair-Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR-Mutant Non-Small Cell Lung Cancer.

A Novel DNA Repair-Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients With EGFR-Mutant Non-Small Cell Lung Cancer.

Journal: Thoracic cancer

Published: October 07, 2024

Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.

Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.

Journal: BMC cancer

Published: May 10, 2024

Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.

Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.

Journal: Oncoimmunology

Published: April 11, 2024

Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.

Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.

Journal: Journal of translational medicine

Published: February 04, 2024

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

Journal: Science bulletin

Published: September 12, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026